{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:16:43Z","timestamp":1768281403780,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T00:00:00Z","timestamp":1471305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40265-016-0630-z","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T14:19:41Z","timestamp":1471357181000},"page":"1373-1379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["IncobotulinumtoxinA: A Review in Upper Limb Spasticity"],"prefix":"10.1007","volume":"76","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,16]]},"reference":[{"issue":"8689","key":"630_CR1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0140-6736(90)90389-M","volume":"335","author":"JW Lance","year":"1990","unstructured":"Lance JW. What is spasticity? Lancet. 1990;335(8689):606.","journal-title":"Lancet."},{"issue":"Suppl 6","key":"630_CR2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/(SICI)1097-4598(1997)6+<169::AID-MUS11>3.0.CO;2-1","volume":"20","author":"DM Simpson","year":"1997","unstructured":"Simpson DM. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve. 1997;20(Suppl 6):169\u201375.","journal-title":"Muscle Nerve."},{"issue":"Suppl 4","key":"630_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1468-1331.2006.01651.x","volume":"13","author":"A Esquenazi","year":"2006","unstructured":"Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol. 2006;13(Suppl 4):27\u201334.","journal-title":"Eur J Neurol."},{"issue":"9","key":"630_CR4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/PHM.0b013e31825f13a3","volume":"91","author":"DK Sommerfeld","year":"2012","unstructured":"Sommerfeld DK, Gripenstedt U, Welmer A-K. Spasticity after stroke: an overview of prevalence, test instruments, and treatments. Am J Phys Med Rehabil. 2012;91(9):814\u201320.","journal-title":"Am J Phys Med Rehabil."},{"issue":"2","key":"630_CR5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1258\/0007142001903111","volume":"56","author":"BB Bhakta","year":"2000","unstructured":"Bhakta BB. Management of spasticity in stroke. Br Med Bull. 2000;56(2):476\u201385.","journal-title":"Br Med Bull."},{"key":"630_CR6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/NDT.S86978","volume":"12","author":"A Santamato","year":"2016","unstructured":"Santamato A. Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity. Neuropsychiatr Dis Treat. 2016;12:251\u201363.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"Suppl 1","key":"630_CR7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1468-1331.2002.0090s1030.x","volume":"9","author":"G Abbruzzese","year":"2002","unstructured":"Abbruzzese G. The medical management of spasticity. Eur J Neurol. 2002;9(Suppl 1):30\u20134.","journal-title":"Eur J Neurol."},{"issue":"2","key":"630_CR8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"J Frevert","year":"2010","unstructured":"Frevert J. Content of botulinum neurotoxin in Botox\u00ae\/Vistabel\u00ae, Dysport\u00ae\/Azzalure\u00ae, and Xeomin\u00ae\/Bocouture\u00ae. Drugs R D. 2010;10(2):67\u201373.","journal-title":"Drugs R D."},{"issue":"1","key":"630_CR9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences. Exp Neurol. 1997;147(1):96\u2013102.","journal-title":"Exp Neurol."},{"issue":"22 Suppl 6","key":"630_CR10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ajhp\/61.suppl_6.S5","volume":"61","author":"RG Wenzel","year":"2004","unstructured":"Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm. 2004;61(22 Suppl 6):S5\u201310.","journal-title":"Am J Health Syst Pharm."},{"key":"630_CR11","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/DDDT.S79193","volume":"9","author":"WH Jost","year":"2015","unstructured":"Jost WH, Benecke R, Hauschke D, et al. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015;9:1913\u201326.","journal-title":"Drug Des Devel Ther."},{"issue":"2\u20133","key":"630_CR12","first-page":"238","volume":"9","author":"J Bl\u00fcmel","year":"2006","unstructured":"Bl\u00fcmel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit. Neurotox Res. 2006;9(2\u20133):238.","journal-title":"Neurotox Res."},{"issue":"5","key":"630_CR13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","volume":"67","author":"WH Jost","year":"2007","unstructured":"Jost WH, Bl\u00fcmel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin\u00ae) in focal dystonia. Drugs. 2007;67(5):669\u201383.","journal-title":"Drugs."},{"key":"630_CR14","unstructured":"Merz Pharmaceuticals LLC. Xeomin (incobotulinumtoxinA) for injection, for intramuscular use: US prescribing information. 2015. http:\/\/www.xeomin.com\/ . Accessed 11 Aug 2016."},{"key":"630_CR15","unstructured":"Merz Pharma UK Ltd. Xeomin 100 units: summary of product characteristics. 2014. http:\/\/www.medicines.org.uk\/ . Accessed 11 Aug 2016."},{"issue":"Suppl 4","key":"630_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2006.01648.x","volume":"13","author":"JO Dolly","year":"2006","unstructured":"Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13(Suppl 4):1\u20139.","journal-title":"Eur J Neurol."},{"issue":"3","key":"630_CR17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/mus.24776","volume":"53","author":"EP Elovic","year":"2016","unstructured":"Elovic EP, Munin MC, Ka\u0148ovsk\u00fd P, et al. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle Nerve. 2016;53(3):415\u201321.","journal-title":"Muscle Nerve."},{"issue":"5","key":"630_CR18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","volume":"32","author":"P Ka\u0148ovsk\u00fd","year":"2009","unstructured":"Ka\u0148ovsk\u00fd P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259\u201365.","journal-title":"Clin Neuropharmacol."},{"key":"630_CR19","doi-asserted-by":"crossref","unstructured":"Elovic E, Munin MC, Ka\u0148ovsk\u00fd P, et al. Efficacy and safety of repeated incobotulinumtoxinA injections for upper-limb post-stroke spasticity [abstract]. In: Annual Assembly of the AAPM&R. 2015.","DOI":"10.1016\/j.pmrj.2015.06.095"},{"issue":"6","key":"630_CR20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","volume":"43","author":"P Ka\u0148ovsk\u00fd","year":"2011","unstructured":"Ka\u0148ovsk\u00fd P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011;43(6):486\u201392.","journal-title":"J Rehabil Med."},{"issue":"4","key":"630_CR21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.2010.01354.x","volume":"122","author":"M Barnes","year":"2010","unstructured":"Barnes M, Schnitzler A, Medeiros L, et al. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies: a randomized parallel-group study. Acta Neurol Scand. 2010;122(4):295\u2013302.","journal-title":"Acta Neurol Scand."},{"issue":"Suppl 1","key":"630_CR22","doi-asserted-by":"crossref","first-page":"57S","DOI":"10.1177\/03946320120250S109","volume":"25","author":"P Fiore","year":"2012","unstructured":"Fiore P, Santamato A, Ranieri M, et al. Treatment of upper limb spasticity after stroke: one-year safety and efficacy of botulinum toxin type A NT201. Int J Immunopathol Pharmacol. 2012;25(Suppl 1):57S\u201362S.","journal-title":"Int J Immunopathol Pharmacol."},{"key":"630_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86:1\u20139.","journal-title":"Neurology."},{"issue":"2","key":"630_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/tsr1902-115","volume":"19","author":"R Teasell","year":"2012","unstructured":"Teasell R, Foley N, Pereira S, et al. Evidence to practice: botulinum toxin in the treatment of spasticity post stroke. Top Stroke Rehabil. 2012;19(2):115\u201321.","journal-title":"Top Stroke Rehabil."},{"key":"630_CR25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","volume":"120","author":"M Naumann","year":"2013","unstructured":"Naumann M, Boo LM, Ackerman AH, et al. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120:275\u201390.","journal-title":"J Neural Transm."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0630-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0630-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0630-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T16:17:56Z","timestamp":1568305076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0630-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,16]]},"references-count":25,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0630-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,16]]}}}